Eli Lilly has struck a deal to buy the near-global rights to a P2X7 receptor antagonist from Asahi Kasei Pharma. The agreement will give Lilly control of a treatment for neuroinflammatory pain conditions that recently completed phase 1 studies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,